Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 21, 2023
Discovery & Translation
Epigenome editing for X-linked diseases; plus a rapid platform for human mAb generation and more
BioCentury’s roundup of translational news
BioCentury | Dec 17, 2022
Product Development
Neoantigens Part III: Picking up the pace
The field ends a busy 4Q22 with Moderna’s highly anticipated, heavily scrutinized data
BioCentury | Oct 12, 2021
Product Development
Allogeneic CAR T data keep CRISPR Therapeutics competitive
Readout does not shed light on concerns of unintended edits
BioCentury | Nov 14, 2020
Product Development
ASH 2020 snapshot: efficacy data in hot emerging areas
A roundup of clinical trial readouts for CD47 blockers, allogeneic CAR T cells and sickle cell disease
BioCentury | Nov 12, 2020
Product Development
Lining up allogeneic CAR Ts at ASH: Data Byte
Promising efficacy data from China’s Bioheng are among the allogeneic CAR T cell updates at ASH this year. The past year has seen a growing number of clinical readouts for off-the-shelf
BioCentury | Oct 22, 2020
Product Development
CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies
CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host
BioCentury | Jul 31, 2019
Preclinical News
July 31 Preclinical Quick Takes: Sangamo reveals new gene editors; plus a CRISPR prediction model and vaccine boosters for ischemia
BioCentury | Dec 8, 2017
Targets & Mechanisms
Pathways emerging from ASH
An analysis of emerging targets at ASH by mechanism
Items per page:
1 - 10 of 11